Get the Stockscreener App
12.45
5.51%
0.65
After Hours:
12.29
-0.16
-1.29%
Bioventus Inc stock is traded at $12.45, with a volume of 822.78K.
It is up +5.51% in the last 24 hours and up +27.30% over the past month.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
See More
Previous Close:
$11.80
Open:
$12.15
24h Volume:
822.78K
Relative Volume:
1.28
Market Cap:
$843.46M
Revenue:
$568.09M
Net Income/Loss:
$27.27M
P/E Ratio:
38.00
EPS:
0.3276
Net Cash Flow:
$71.41M
1W Performance:
+7.51%
1M Performance:
+27.30%
6M Performance:
+57.20%
1Y Performance:
+89.50%
1-Day Range:
$11.90
$12.49
1-Week Range:
$11.35
$12.49
52-Week Range:
$5.81
$12.53
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
12.45 | 799.43M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | CJS Securities | Market Outperform |
| Feb-09-26 | Initiated | Barrington Research | Outperform |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
BlackRock (BVS) discloses 3.4M-share, 5.02% passive stake in Bioventus - Stock Titan
Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Bioventus Inc (BVS) Balance Sheet - TradingKey
Bioventus Inc (BVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bioventus Inc (BVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bioventus Inc (BVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BVS|Bioventus Inc|Price:11.800|Chg%:+0.320 - TradingKey
TradingKey - TradingKey
Bioventus, Inc. (BVS) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect? - Yahoo Finance
161,926 Shares in Bioventus Inc. $BVS Acquired by Fifth Third Bancorp - MarketBeat
Bioventus Inc (BVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Understanding the Setup: (BVS) and Scalable Risk - Stock Traders Daily
Bioventus Inc (BVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bioventus (BVS) Upgraded to Buy: Here's Why - Yahoo Finance
Should Value Investors Buy Bioventus (BVS) Stock? - Yahoo Finance
Bioventus (BVS) Q4 2025 earnings summary - Quartr
Bioventus (BVS) Proxy filing Summary - Quartr
Bioventus (BVS) Q3 2024 earnings summary - Quartr
Bioventus (BVS) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary - Quartr
Bioventus (BVS) Q2 2024 earnings summary - Quartr
Bioventus (BVS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Bioventus (BVS) Q1 2026 earnings summary - Quartr
Bioventus (BVS) Corporate presentation Summary - Quartr
Bioventus, Inc. (BVS) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
A Look at Bioventus Inc (BVS) After 4.1% Decline -- GF Value $6. - GuruFocus
Bioventus Down Nearly 9%, On Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Bioventus (NASDAQ:BVS) Reaches New 12-Month HighHere's Why - MarketBeat
Hillsdale Investment Management Inc. Raises Stake in Bioventus Inc. $BVS - MarketBeat
Bioventus Inc. (NASDAQ:BVS) Given Average Rating of "Buy" by Brokerages - MarketBeat
Bioventus Q1 2026 Earnings: EPS Beat Exceeds Estimates, But Stock SlipsPositive Surprise Momentum - dars.gov.et
Bioventus Slips Amid Selling Pressure: Key Levels to Watch for BVSFair Value Gap - dars.gov.et
Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks - Yahoo Finance
Bioventus, Inc. Class A Actuals & Estimates (LSX:A2APNA) - TradingView
Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice - Yahoo Finance
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $16 - Moomoo
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know - Yahoo Finance
Bioventus Deadline Alert - TMX Newsfile
A2APNA Forecast — Price Target — Prediction for 2027 - TradingView
A2APNA Stock Price and Chart — LSX:A2APNA - TradingView
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade) (NASDAQ:BVS) - Seeking Alpha
BioventusTargeting Earnings Growth Outpacing Revenue Growth In 2026 - RTTNews
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Zacks.com featured highlights include First Advantage, Bioventus and Ooma - Yahoo Finance
Bioventus stock surges on favorable 2027 outpat... - Pluang
Bioventus shares rise after Medicare reverses reimbursement cuts By Investing.com - Investing.com Canada
Bioventus shares rise after Medicare reverses reimbursement cuts - Investing.com
Bioventus Shareholder Action Reminder - TMX Newsfile
Bioventus Shareholder Notice - TMX Newsfile
Total liabilities of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Free cash flow of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):